Shares of Immunomedics, Inc. (NASDAQ:IMMU) ended Thursday session in green amid volatile trading. The shares closed up +0.13 points or 4.55% at $2.99 with 817,858.00 shares getting traded. Post opening the session at $2.85, the shares hit an intraday low of $2.79 and an intraday high of $2.99 and the price vacillated in this range throughout the day. The company has a market cap of $289.68 million and the numbers of outstanding shares have been calculated to be 95.87 million shares.
Immunomedics, Inc. (IMMU) on Aug. 31, 2016 announced that it will present at upcoming investor conference:
Rodman & Renshaw 18th Annual Global Investment Conference at 4:15 pm on Tuesday, September 13, 2016 at the Lotte New York Palace Hotel in New York City.
The Company will also participate in one-on-one meetings with institutional investors at this conference.
Shares of Sanofi SA (ADR) (NYSE:SNY) ended Thursday session in green amid volatile trading. The shares closed up +0.49 points or 1.24% at $40.09 with 2.80 million shares getting traded. Post opening the session at $39.93, the shares hit an intraday low of $39.86 and an intraday high of $40.18 and the price vacillated in this range throughout the day. The company has a market cap of $103.95 billion and the numbers of outstanding shares have been calculated to be 1.29 billion shares.
Sanofi SA (ADR) (SNY) on July 29, 2016 Announced Q2 2016 Results.
Sanofi Chief Executive Officer, Olivier Brandicourt, commented:
“Our second quarter financial performance was in-line with expectations despite anticipated headwinds. Sanofi Genzyme grew 20% and, although Dengvaxia® uptake has been delayed, Sanofi Pasteur performed well. Recent highlights included the signing of the CHC asset swap, the approval of Praluent® in several countries and positive Phase III CHRONOS data for dupilumab. Following our first half performance, we confirm our broadly stable 2016 Business EPS guidance at CER.”
Second quarter financial results and 2016 guidance confirmed
- Aggregate Company sales decreased 0.2% (down 4.3% at 2016 exchange rates) to €8,868 million. Excluding Venezuela, Aggregate Company sales grew 1.9%
- Business EPS was down 2.1% at CER to €1.31 and down 7.1% on a reported basis
- Sanofi continues to expect 2016 Business EPS to be broadly stable at CER, barring unforeseen major adverse events